Cost-effectiveness of 44 mcg subcutaneous interferon beta-1a (scIFNβ1a) and 30 mcg intramuscular interferon beta-1a (imIFNβ1a) using clinical endpoints of disease activity

被引：0
|
作者：
Phillips, A. L. [1 ]
Edwards, N. C. [2 ]
Locklear, J. C. [1 ]
机构：
[1] EMD Serono Inc, Rockland, MA USA
[2] Hlth Serv Consulting Corp, Boxboro, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2015年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P839
引用
收藏
页码：421 / 421
页数：1
相关论文
共 50 条
  • [21] Characteristics and treatment patterns of older ms patients treated with peginterferon beta-1a or intramuscular interferon beta-1a in the real world
    Vignos, M.
    Altincatal, A.
    Mendoza, J.
    Avila, R.
    Makin, C.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 520 - 520
  • [22] Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States
    Hernandez, Luis
    Guo, Shien
    Kinter, Elizabeth
    Fay, Monica
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (07) : 684 - 695
  • [23] COST-EFFECTIVENESS OF FINGOLIMOD, TERIFLUNOMIDE, DIMETHYL FUMARATE AND INTRAMUSCULAR INTERFERON BETA-1A IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Zhang, X.
    Hay, J. W.
    VALUE IN HEALTH, 2014, 17 (03) : A59 - A60
  • [24] COMPARISON OF MEDICATION ADHERENCE TO INTERFERON BETA-1B AND INTERFERON BETA-1A SUBCUTANEOUS IN MULTIPLE SCLEROSIS PATIENTS
    Meletiche, D. M.
    Kozma, C.
    Dickson, M.
    VALUE IN HEALTH, 2009, 12 (03) : A194 - A194
  • [25] A cost-effectiveness analysis of subcutaneous interferon-β-1a 44mcg three times a week versus no treatment for patients with a single demyelinating event in Sweden
    Fredrikson, S.
    McLeod, E.
    Henry, N.
    Pitcher, A.
    Cuche, M.
    Fajutrao, L.
    Perard, R.
    Bates, D.
    Chan, A.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 114 - 114
  • [26] COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF SUBCUTANEOUS INTERFERON BETA-1A FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
    Espallardo, O.
    Crespo, C.
    Polanco, C.
    Nieves, D.
    VALUE IN HEALTH, 2009, 12 (07) : A366 - A367
  • [27] Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration
    Munafo, A
    Trinchard-Lugan, I
    Nguyen, TXQ
    Buraglio, M
    EUROPEAN JOURNAL OF NEUROLOGY, 1998, 5 (02) : 187 - 193
  • [28] Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration
    Munafo, A
    Trinchard-Lugan, I
    Xuan, T
    Ho-Nguyen, Q
    Buraglio, M
    EUROPEAN JOURNAL OF NEUROLOGY, 1999, 6 (03) : 376 - 377
  • [29] Subcutaneous Interferon Beta-1a in Pediatric Multiple Sclerosis: A Retrospective Study
    Tenembaum, Silvia N.
    Banwell, Brenda
    Pohl, Daniela
    Krupp, Lauren B.
    Boyko, Alexey
    Meinel, Michael
    Lehr, Lorenz
    Rocak, Sanda
    di Cantogno, Elisabetta Verdun
    Moraga, Margaretha Stam
    Ghezzi, Angelo
    JOURNAL OF CHILD NEUROLOGY, 2013, 28 (07) : 849 - 856
  • [30] Cost-Effectiveness of Early Initiation of Fingolimod Versus Delayed Initiation After 1 Year of Intramuscular Interferon Beta-1a in Patients with Multiple Sclerosis
    Agashivala, Neetu
    Kim, Edward
    CLINICAL THERAPEUTICS, 2012, 34 (07) : 1583 - 1590
12345